Blog | BioInformant

MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Knee Osteoarthritis

July 5, 2026 By BioInformant Team Leave a Comment

U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects

CAMBRIDGE, Mass.–MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced today the treatment of the first U.S. participant in its Phase III clinical trial evaluating its investigational mesenchymal stem cell (MSC) therapy to treat symptomatic cartilage defects in adults with knee osteoarthritis. The FDA has agreed that this single pivotal study, supported by confirmatory evidence from prior Phase 3 trials in South Korea and Japan together with Korean real-world evidence, can serve as the basis for MEDIPOST’s planned U.S. BLA filing. The milestone marks a significant step forward in MEDIPOST’s mission to bring a first-of-its-kind regenerative therapy to patients in the United States. This procedure was performed by Dr. Justin Newman at Orthopedic Centers of Colorado. [Read more…]

Osaka’s Cell Grand Clinic Named Top Regenerative Medicine Solution Provider in APAC 2026 — Standardizes Patient-Specific ADSC Therapy Across 13 Government-Certified Programs

June 30, 2026 By BioInformant Team Leave a Comment

Japanese government-certified clinic applies ISCT-compliant flow-cytometry release criteria to patient-specific adipose-derived stem cell cultures, serving patients from approximately 20 countries [Read more…]

UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson’s Therapy

June 29, 2026 By BioInformant Team Leave a Comment

SHANGHAI, June 23, 2026 — UniXell Biotechnology Co., Ltd. (“UniXell”) has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for UX-DA003, its allogeneic induced pluripotent stem cell (iPSC)-derived therapy for Parkinson’s disease. Paired with the prior IND approval from China’s National Medical Products Administration (NMPA) on June 3, 2026, the candidate will undergo clinical development in both China and the United States concurrently, marking a landmark dual-country breakthrough for the company’s neurodegenerative disease pipeline. This milestone solidifies UniXell’s unique dual-pathway clinical strategy covering personalized autologous and scalable off-the-shelf allogeneic iPSC therapeutics.

[Read more…]

Anja Health Expands Partnership with Vitalant Cord Blood Stem Cell Laboratory to Advance Newborn Stem Cell Preservation

June 28, 2026 By BioInformant Team Leave a Comment

More Than 100 Years of Combined Experience Supporting Families and the Future of Regenerative Medicine

LOS ANGELES, CA, UNITED STATES, June 16, 2026 — Anja Health, a leading provider of newborn stem cell preservation services, announced the expansion of its partnership with the Vitalant Cord Blood Stem Cell Laboratory, one of the nation’s most respected stem cell processing and storage facilities, further strengthening Anja Health’s commitment to providing families with advanced cord blood, cord tissue, and placenta stem cell preservation services. [Read more…]

Cord for Life® Completes the First Clinical Trial Using Cord Blood Stem Cells for a Non-Transplant Medical Treatment of Lower Back Pain

June 27, 2026 By BioInformant Team Leave a Comment

ALTAMONTE SPRINGS, Fla. — In a historical moment for umbilical cord blood stem cell research, Cord for Life®, Inc. announces the completion of phase 1 of a clinical trial for lower back pain treatment. This marks the first time umbilical cord blood stem cells have been evaluated for a treatment not related to transplantation and regeneration of the recipient’s bone marrow to generate new blood cells. This early success could lead to numerous other trials for a wide range of treatments that could have a significant effect on the quality of life for tens of millions of patients worldwide. [Read more…]